San Diego, CA – November 8, 2009 — HUYA Bioscience International, a leader in globalizing China’s biopharmaceutical innovation, today announced a strategic partnership with the School of Medicine and Pharmacy, Ocean University of China. The agreement is another in a series of collaborations that HUYA has established with China’s leading research and development institutions to enable and accelerate the global development and commercialization of novel biopharmaceutical product opportunities originating in China. Read more
Brussels – May 18, 2009 — Solvay Pharmaceuticals announces it has signed an agreement with HUYA Bioscience International, a company specialized in enabling and accelerating global co- development of novel biopharmaceutical product opportunities originating in China.
Through this agreement, Solvay Pharmaceuticals will gain access to HUYA’s comprehensive Chinese molecule portfolio, focusing specifically on compounds in the cardiovascular area. As some of these molecules are already in advanced stages of development in China, the partnership will help Solvay Pharmaceuticals speed up its early discovery activities as well as increase the company’s chances for successfully developing innovative new therapies as safety or efficacy information is already available for some of these molecules. Read more
Collaboration will leverage HUYA’s growing Chinese bioscience network
San Diego, CA – April 21, 2009 — HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical drug candidates that originate in China.
Abbott will gain access to HUYA’s growing Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. HUYA has agreements in place with many of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. HUYA is currently evaluating and following the progress of more than 600 lead, preclinical and clinical drug candidates. Read more
HUYA to Collaborate on Pre-clinical and Clinical Studies for Chinese Drugs
San Diego, CA – February 18, 2009 — HUYA Bioscience International, the leader in US/China pharmaceutical co-development, today announced a partnership agreement with the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College (collectively – The Beijing Institute of Materia Medica, BIMM). The agreement grants HUYA the opportunity to collaborate with BIMM on pre-clinical safety and efficacy, and clinical trial protocols. The agreement also provides HUYA with the right of first review and negotiation for the licensing and development of certain new compounds owned or controlled by BIMM. This right includes drugs in discovery and development for use in the areas of cardiology, endocrinology, oncology, immunology, hematology, neuroscience and anti-infectives. Read more